Acer Therapeutics (NASDAQ:ACER) Stock Sees High Volatility: A Good Buy Now?
Pharmaceutical company focusing on acquisition and commercialisation of therapies for serious rare and life-threatening diseases, Acer Therapeutics (NASDAQ:ACER),announced on July 29, 2021 that after recent Type B meeting with U.S. FDA on Acer’s proposed EDSIVO development plan, the firm plans a pivotal clinical trial in patients with COL3A1+ vascular Ehlers-Danlos Syndrome. The firm in 2021 second half aims to submit protocol for prospective study in addition to investigational new drug…